Pipeline
Curasight follows a theranostic approach using its uPAR radionuclide platform to improve both diagnosis and the treatment of certain types of cancer. The company is developing its uTREAT® therapeutic platform and its uTRACE® diagnostic platform in parallel and has a business development strategy to find partners for later stage clinical development and potential commercialisation.
![](/images/4b2f5071-d04a-4880-b493-9e26af85c9b3/dt/Pipeline-1.png)
![](/images/85866226-980b-433c-89a5-2a8b1eef00e5/dt/Pipeline-2.png)
![](/images/02c039bd-30d6-4e3f-87a8-aec261d004b1/dt/Pipeline-3.png)